



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : Attorney Docket No. 2006_0978A
Peter HEROLD et al. : **Confirmation No. 8786**
Serial No. 10/587,046 : Group Art Unit 1626
Filed July 24, 2006 : Examiner Golam M. Shameem
AMINO ALCOHOL DERIVATIVES AND : **Mail Stop: ISSUE FEE**
THEIR USE AS RENIN INHIBITOR

ADDENDUM TO STATEMENT UNDER 37 CFR §3.73(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


The Consent of Assignee and Statement Under 37 CFR §3.73(b) submitted herewith refers to the Reel and Frame number which shows that Speedel Experimenta AG assigned its rights in the above-identified application to Novartis AG. The Assignment of the application from the inventors to Speedel Experimenta AG was previously recorded on July 24, 2006 at Reel 018096, Frame 0317. Accordingly, it is apparent that the chain of title from the inventors to Novartis AG is established by the Assignment records of the U.S. Patent and Trademark Office.

Respectfully submitted,

Peter HEROLD et al.

By Michael R. Davis
Michael R. Davis
Registration No. 25,134
Attorney for Applicants

MRD/pth
Washington, D.C. 20005-1503
Telephone (202) 721-8200
Facsimile (202) 721-8250
March 12, 2010



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : Attorney Docket No. 2006_0978A
Peter HEROLD et al. : Confirmation No. 8786
Serial No. 10/587,046 : Group Art Unit 1626
Filed July 24, 2006 : Examiner Golam M. Shameem
AMINO ALCOHOL DERIVATIVES AND : Mail Stop: ISSUE FEE
THEIR USE AS RENIN INHIBITOR

CONSENT OF ASSIGNEE AND STATMENT UNDER 37 CFR §3.73(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The undersigned, who is empowered to act on behalf of the actual assignee of the above-identified application, represents that the assignee is the owner of the entire right, title and interest in the above-identified application, as evidenced by a certificate of merger recorded on February 9, 2010 at Reel 023920, Frame 0239 in favor of Novartis AG, and hereby consents to the accompanying Petition Regarding Patent Term Adjustment Under 37 CFR 1.705(b).

NOVARTIS AG

Authorized Signing Officer

Date: MARCH 5, 2010